[Therapeutic indications in symptomatic cognitive and psychopathological disorders in multiple sclerosis].
Cognitive impairment and psychiatric disorders occur in about 60 p. cent of multiple sclerosis patients. In general, impairment develops in established cases, although it can present early in the disease course. The pattern of neuropsychological deficits is characterized by deficits in attention, memory and executive functions; No specific treatment seems to be effective in cognitive impairment but appropriate strategies could limit the negative impact on this disease. Depressive states are twice frequent and usual antidepressant drugs seems to demonstrate some efficacy.
Lebrun
C
C
Service de Neurologie, Hôpital Pasteur, 30, Voie Romaine, BP69, 06002 Nice.
D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003704:Dementia / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D009483:Neuropsychological Tests; D011619:Psychotropic Drugs / Q000008:administration & dosage* / Q000009:adverse effects
D007166:Immunosuppressive Agents; D011619:Psychotropic Drugs
Indications thérapeutiques à visée symptomatique des troubles cognitifs et psychopathologiques dans la sclérose en plaques.